Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Incredible Travel Objections for Craftsmanship Darlings to Visit - 2Chief of Staff Zamir warns IDF will collapse due to lack of manpower, raises 'ten red flags'
- 3Top German court to rule on claims by Wirecard shareholders
- 4Ski Resorts Universally: A Colder time of year Wonderland Guide
- 5Reveal Less popular Authentic Realities You Didn't Learn in School
- Journey Lines for Each Explorer: Track down Your Ideal Journey
- Russia earning billions from Hormuz blockade, German trade body says
- US FDA investigates Takeda's blood disorder drug after pediatric death
- Tech Development Disclosed: A Survey of \Usefulness and Configuration in Concentration\ Tech Item
- The Electric Bicycle Americans Can Confide in 2024
- Emergent Cold LatAm opens state-of-the-art cold storage hub in Guadalajara
- Clovis Unified students spend spring break traveling through China
- 'We need everyone,' wounded reservist urges Knesset panel to advance haredi draft law
- Defense Minister Katz finally condemns Jewish extremist violence against Palestinians
